Scientists are now exploring a promising new approach to treating long Covid, a chronic condition that affects millions worldwide. The focus is on Zepbound, a weight loss medication known as tirzepatide, which may help alleviate the debilitating symptoms of this illness.
Research has shown that tirzepatide can reduce inflammation throughout the body - a hallmark feature of many diseases. With long Covid characterized by persistent inflammation, scientists believe that reducing or eliminating it could lead to significant improvements in patients' symptoms.
Currently, studies have documented over 200 possible symptoms associated with long Covid. The most common ones include respiratory issues like coughing and shortness of breath, as well as neurological problems such as brain fog and mood swings.
In an ongoing US-wide trial, researchers are testing tirzepatide to see if it can effectively treat patients with long Covid. This study will recruit 1,000 participants aged 18 or older across the country who have experienced long Covid symptoms for at least three months.
The unique aspect of this trial is that it's fully remote - meaning participants receive their treatment via mail rather than in-person. The researchers also want to monitor participants' activity levels using fitness trackers and weight them regularly.
Previous studies have shown that tirzepatide could be beneficial for patients with mast cell activation syndrome, a condition closely linked to long Covid symptoms. In such cases, the medication has resulted in significant improvements.
Private practice physician David Kaufman notes that some of his patients took the drug off-label after experiencing decreased fatigue while taking it to manage weight. However, caution must be exercised - this doesn't cure everything but could potentially improve overall well-being for those with long Covid.
For those with severe symptoms or unable to travel, remote clinical trials provide an ideal alternative to traditional in-person treatments.
Research has shown that tirzepatide can reduce inflammation throughout the body - a hallmark feature of many diseases. With long Covid characterized by persistent inflammation, scientists believe that reducing or eliminating it could lead to significant improvements in patients' symptoms.
Currently, studies have documented over 200 possible symptoms associated with long Covid. The most common ones include respiratory issues like coughing and shortness of breath, as well as neurological problems such as brain fog and mood swings.
In an ongoing US-wide trial, researchers are testing tirzepatide to see if it can effectively treat patients with long Covid. This study will recruit 1,000 participants aged 18 or older across the country who have experienced long Covid symptoms for at least three months.
The unique aspect of this trial is that it's fully remote - meaning participants receive their treatment via mail rather than in-person. The researchers also want to monitor participants' activity levels using fitness trackers and weight them regularly.
Previous studies have shown that tirzepatide could be beneficial for patients with mast cell activation syndrome, a condition closely linked to long Covid symptoms. In such cases, the medication has resulted in significant improvements.
Private practice physician David Kaufman notes that some of his patients took the drug off-label after experiencing decreased fatigue while taking it to manage weight. However, caution must be exercised - this doesn't cure everything but could potentially improve overall well-being for those with long Covid.
For those with severe symptoms or unable to travel, remote clinical trials provide an ideal alternative to traditional in-person treatments.